Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205
Public ClinicalTrials.gov record NCT01247922. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Open-label Phase 2 Study of Single-agent Erlotinib for Patients With Pediatric Ependymoma Previously Treated With Oral Etoposide in Protocol OSI-774-205
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Participants that were assigned to the oral etoposide treatment arm in protocol OSI-774-205 and either progressed while on study or discontinued due to unacceptable toxicity related to etoposide were allowed to participate in this study to assess the safety profile of single-agent erlotinib in participants with recurrent or refractory pediatric ependymoma.
Study identification
- NCT ID
- NCT01247922
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 4 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 1 Year to 21 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 23, 2011 (Actual)
- Primary completion
- Sep 13, 2012 (Actual)
- Completion
- Sep 13, 2012 (Actual)
- Last update posted
- Dec 6, 2024
2011 – 2012
United States locations
- U.S. sites
- 11
- U.S. states
- 10
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35233 | — |
| Children's Hospital of Orange County (CHOC) | Orange | California | 92868 | — |
| Packard Children's Hospital | Palo Alto | California | 94304 | — |
| The Children's Hospital Center for Cancer and Blood Disorders | Aurora | Colorado | 80045 | — |
| Children's National Medical Center -D.C. Center for Cancer and Blood Disorders | Washington D.C. | District of Columbia | 20010 | — |
| University of Miami | Miami | Florida | 33136 | — |
| Emory University Children's Healthcare of Atlanta | Atlanta | Georgia | 30322 | — |
| University of Minnesota - Amplatz Children's Hospital | Minneapolis | Minnesota | 55455 | — |
| Oregon Health & Sciences University Doernbecher Children's Hospital | Portland | Oregon | 97124 | — |
| Childrens Hospital of Pittsburgh of UPMC | Pittsburgh | Pennsylvania | 15224 | — |
| University of Wisconsin | Madison | Wisconsin | 53705-2275 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01247922, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 6, 2024 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01247922 live on ClinicalTrials.gov.